Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization.

RATIONALE Outcomes other than spirometry are required to assess nonbronchodilator therapies for chronic obstructive pulmonary disease. Estimates of the minimal clinically important difference for the 6-minute-walk distance (6MWD) have been derived from narrow cohorts using nonblinded intervention. OBJECTIVES To determine minimum clinically important difference for change in 6MWD over 1 year as a function of mortality and first hospitalization in an observational cohort of patients with COPD. METHODS Data from the ECLIPSE cohort were used (n = 2,112). Death or first hospitalization were index events; we measured change in 6MWD in the 12-month period before the event and related change in 6MWD to lung function and St. George's Respiratory Questionnaire (health status). MEASUREMENT AND MAIN RESULTS Of subjects with change in the 6MWD data, 94 died, and 323 were hospitalized. 6MWD fell by 29.7 m (SD, 82.9 m) more among those who died than among survivors (P < 0.001). A reduction in distance of more than 30 m conferred a hazard ratio of 1.93 (95% confidence interval, 1.29-2.90; P = 0.001) for death. No significant difference was observed for first hospitalization. Weak relationships only were observed with change in lung function or health status. CONCLUSIONS A reduction in the 6MWD of 30 m or more is associated with increased risk of death but not hospitalization due to exacerbation in patients with chronic obstructive pulmonary disease and represents a clinically significant minimally important difference.

[1]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[2]  L. Edwards,et al.  Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. , 2012, Journal of the American Medical Directors Association.

[3]  A. Høiseth,et al.  Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease , 2011, Thorax.

[4]  S. Sahn,et al.  Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. , 2011, American journal of respiratory and critical care medicine.

[5]  K. Meijer,et al.  Reproducibility of 6-minute walking test in patients with COPD , 2010, European Respiratory Journal.

[6]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[7]  Edwin K Silverman,et al.  Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.

[8]  M. Polkey,et al.  Sniff nasal inspiratory pressure versus IC/TLC ratio as predictors of mortality in COPD. , 2010, Respiratory medicine.

[9]  B. Make,et al.  The minimal important difference of exercise tests in severe COPD , 2010, European Respiratory Journal.

[10]  L. Edwards,et al.  Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. , 2010, Respiratory medicine.

[11]  A. Holland,et al.  Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease. , 2010, Archives of physical medicine and rehabilitation.

[12]  B. Celli,et al.  The modified BODE index: validation with mortality in COPD , 2008, European Respiratory Journal.

[13]  G. Guyatt,et al.  Interpretation of treatment changes in 6-minute walk distance in patients with COPD , 2008, European Respiratory Journal.

[14]  W. MacNee,et al.  Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) , 2008, European Respiratory Journal.

[15]  T. Seemungal,et al.  COPD exacerbations: defining their cause and prevention , 2007, The Lancet.

[16]  R. Porcher,et al.  Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease , 2006, Thorax.

[17]  K. Swedberg,et al.  Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. , 2005, European heart journal.

[18]  J. Kiley,et al.  Challenges Associated with Estimating Minimal Clinically Important Differences in COPD—The NHLBI Perspective , 2005, COPD.

[19]  B. Celli,et al.  The 6‐min walk distance: change over time and value as a predictor of survival in severe COPD , 2004, European Respiratory Journal.

[20]  Steven Piantadosi,et al.  A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. , 2003, The New England journal of medicine.

[21]  M. Decramer,et al.  Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. , 2000, The American journal of medicine.

[22]  D A Redelmeier,et al.  Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. , 1997, American journal of respiratory and critical care medicine.

[23]  R. Peslin,et al.  Symbols, abbreviations and units. Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. , 1993, The European respiratory journal. Supplement.

[24]  R. Peslin,et al.  Symbols, abbreviations and units , 1993, European Respiratory Journal.